Elizabeth A Raetz

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. doi request reprint Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?
    Elizabeth A Raetz
    Division of Pediatric Hematology Oncology, New York University Langone Medical Center, New York, NY, USA
    Hematology Am Soc Hematol Educ Program 2012:129-36. 2012
  2. pmc Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]
    Elizabeth A Raetz
    New York University School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, 160 E 32nd St, New York, NY 10016, USA
    J Clin Oncol 26:3971-8. 2008
  3. doi request reprint Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia
    Elizabeth A Raetz
    Division of Pediatric Hematology Oncology, Department of Pediatrics, New York University School of Medicine, New York, NY 10016, USA
    J Pediatr Hematol Oncol 32:554-63. 2010
  4. pmc Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study
    Elizabeth A Raetz
    Department of Pediatrics, New York University, School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, New York, NY 10016, USA
    J Clin Oncol 26:3756-62. 2008
  5. pmc Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]
    Deepa Bhojwani
    Division of Pediatric Hematology Oncology, New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    J Clin Oncol 26:4376-84. 2008
  6. pmc Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance
    Nicholas A Vitanza
    Department of Pediatric Hematology Oncology, Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical Center, New York, New York
    Pediatr Blood Cancer 61:1779-85. 2014
  7. ncbi request reprint Childhood acute lymphoblastic leukemia in the age of genomics
    William L Carroll
    Division of Pediatric Hematology Oncology, New York University Cancer Institute, New York University School of Medicine, New York City, New York, USA
    Pediatr Blood Cancer 46:570-8. 2006
  8. ncbi request reprint Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia
    Deepa Bhojwani
    NYU Cancer Institute, Division of Pediatric Hematology, New York University School of Medicine, New York, New York 10016, USA
    Paediatr Drugs 9:149-56. 2007
  9. pmc Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4
    Anne L Angiolillo
    Anne L Angiolillo, Reuven J Schore, Ashley R Lane, and Gregory H Reaman, Children s National Medical Center, Washington, DC Meenakshi Devidas, Colleges of Medicine, Public Health and Health Professions, University of Florida Charlotte Wood and Hao W Zheng, Children s Oncology Group, Gainesville, FL Michael J Borowitz, Johns Hopkins Medical Institutions, Baltimore Taha Keilani, Sigma tau Pharmaceuticals, Gaithersburg, MD Andrew J Carroll, University of Alabama at Birmingham, Birmingham, AL Julie M Gastier Foster and Nyla A Heerema, Ohio State University Wexner Medical Center Julie M Gastier Foster, Ohio State University College of Medicine and Nationwide Children s Hospital, Columbus, OH Mignon L Loh, University of California at San Francisco, San Francisco, CA Peter C Adamson, Children s Hospital of Philadelphia, Philadelphia, PA Brent Wood, University of Washington, Seattle, WA Elizabeth A Raetz and William L Carroll, New York University Cancer Institute, New York University Langone Medical Center, New York, NY Naomi J Winick, University of Texas Southwestern Medical Center, Boston
    J Clin Oncol 32:3874-82. 2014
  10. pmc Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study
    Deepa Bhojwani
    New York University NYU Cancer Institute and Division of Pediatric Hematology Oncology, NY 10016, USA
    Blood 108:711-7. 2006

Collaborators

Detail Information

Publications24

  1. doi request reprint Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?
    Elizabeth A Raetz
    Division of Pediatric Hematology Oncology, New York University Langone Medical Center, New York, NY, USA
    Hematology Am Soc Hematol Educ Program 2012:129-36. 2012
    ..Recently, high-resolution genomic analyses of matched pairs of diagnostic and relapse bone marrow samples are emerging as a promising tool for identifying pathways that impart chemoresistance...
  2. pmc Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]
    Elizabeth A Raetz
    New York University School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, 160 E 32nd St, New York, NY 10016, USA
    J Clin Oncol 26:3971-8. 2008
    ..The goal of the Children's Oncology Group (COG) AALL01P2 study was to develop a safe and active chemotherapy reinduction platform, which could be used to evaluate novel agents in future trials...
  3. doi request reprint Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia
    Elizabeth A Raetz
    Division of Pediatric Hematology Oncology, Department of Pediatrics, New York University School of Medicine, New York, NY 10016, USA
    J Pediatr Hematol Oncol 32:554-63. 2010
    ..The spectrum of common toxicities and the efficacy of different formulations of L-ASNase are presented in this review...
  4. pmc Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study
    Elizabeth A Raetz
    Department of Pediatrics, New York University, School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, New York, NY 10016, USA
    J Clin Oncol 26:3756-62. 2008
    ....
  5. pmc Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]
    Deepa Bhojwani
    Division of Pediatric Hematology Oncology, New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
    J Clin Oncol 26:4376-84. 2008
    ..To identify children with acute lymphoblastic leukemia (ALL) at initial diagnosis who are at risk for inferior response to therapy by using molecular signatures...
  6. pmc Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance
    Nicholas A Vitanza
    Department of Pediatric Hematology Oncology, Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical Center, New York, New York
    Pediatr Blood Cancer 61:1779-85. 2014
    ..Additionally, IKZF1 deletions and mutations identify high-risk biological subsets of childhood ALL [Georgopoulos et al. Cell 1995;83(2):289-299; Mullighan et al. N Engl J Md 2009;360(5):470-480]...
  7. ncbi request reprint Childhood acute lymphoblastic leukemia in the age of genomics
    William L Carroll
    Division of Pediatric Hematology Oncology, New York University Cancer Institute, New York University School of Medicine, New York City, New York, USA
    Pediatr Blood Cancer 46:570-8. 2006
    ..New bioinformatics tools optimize data mining, but validation of findings is essential since "over-fitting" the data is a common danger. In the future, genomic analysis will be complemented by evaluation of the cancer proteome...
  8. ncbi request reprint Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia
    Deepa Bhojwani
    NYU Cancer Institute, Division of Pediatric Hematology, New York University School of Medicine, New York, New York 10016, USA
    Paediatr Drugs 9:149-56. 2007
    ..These newer methods of genome analyses complemented by studies involving the proteome as well as host polymorphisms will have a profound impact on the diagnosis and management of childhood ALL...
  9. pmc Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4
    Anne L Angiolillo
    Anne L Angiolillo, Reuven J Schore, Ashley R Lane, and Gregory H Reaman, Children s National Medical Center, Washington, DC Meenakshi Devidas, Colleges of Medicine, Public Health and Health Professions, University of Florida Charlotte Wood and Hao W Zheng, Children s Oncology Group, Gainesville, FL Michael J Borowitz, Johns Hopkins Medical Institutions, Baltimore Taha Keilani, Sigma tau Pharmaceuticals, Gaithersburg, MD Andrew J Carroll, University of Alabama at Birmingham, Birmingham, AL Julie M Gastier Foster and Nyla A Heerema, Ohio State University Wexner Medical Center Julie M Gastier Foster, Ohio State University College of Medicine and Nationwide Children s Hospital, Columbus, OH Mignon L Loh, University of California at San Francisco, San Francisco, CA Peter C Adamson, Children s Hospital of Philadelphia, Philadelphia, PA Brent Wood, University of Washington, Seattle, WA Elizabeth A Raetz and William L Carroll, New York University Cancer Institute, New York University Langone Medical Center, New York, NY Naomi J Winick, University of Texas Southwestern Medical Center, Boston
    J Clin Oncol 32:3874-82. 2014
    ..COG AALL07P4 was designed to determine the pharmacokinetic and pharmacodynamic comparability of SC-PEG to SS-PEG in patients with newly diagnosed high-risk (HR) B-cell ALL...
  10. pmc Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study
    Deepa Bhojwani
    New York University NYU Cancer Institute and Division of Pediatric Hematology Oncology, NY 10016, USA
    Blood 108:711-7. 2006
    ..These results suggest that early-relapse results from the emergence of a related clone, characterized by the up-regulation of genes mediating cell proliferation. In contrast, late relapse appears to be mediated by diverse pathways...
  11. pmc Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia
    Teena Bhatla
    New York University Cancer Institute, New York University Langone Medical Center, New York, NY 10016, USA
    Blood 119:5201-10. 2012
    ..Incorporation of these targeted epigenetic agents to the standard chemotherapy backbone is a promising approach to the treatment of relapsed pediatric acute lymphoblastic leukemia...
  12. ncbi request reprint Building better therapy for children with acute lymphoblastic leukemia
    William L Carroll
    Stephen D Hassenfeld Children s Center for Cancer and Blood Diseases, New York University Cancer Institute, New York, New York 10016, USA
    Cancer Cell 7:289-91. 2005
    ..The goal is now to integrate these and other findings using gene expression technology into the care of children with the most common pediatric malignancy...
  13. pmc Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia
    Smita Dandekar
    NYU Langone Medical Center, NYU Cancer Institute, New York, NY, USA
    Br J Haematol 167:87-99. 2014
    ..Our results demonstrate that overactivation of the Wnt pathway may contribute to chemoresistance in relapsed childhood ALL and that Wnt-inhibition may be a promising therapeutic approach. ..
  14. pmc The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions
    Teena Bhatla
    Division of Pediatric Hematology Oncology, New York University Cancer Institute, New York University Langone Medical Center, New York, NY
    J Pediatr Hematol Oncol 36:413-8. 2014
    ..Herein, we summarize results using a variety of genomic technologies to highlight the power of this methodology in providing insight into the biological mechanisms that impart resistant disease. ..
  15. pmc Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group
    Nyla A Heerema
    Nyla A Heerema and Julie M Gastier Foster, The Ohio State University Wexner Medical Center Julie M Gastier Foster, The Ohio State University College of Medicine and Nationwide Children s Hospital, Columbus, OH Andrew J Carroll, University of Alabama at Birmingham, Birmingham, AL Meenakshi Devidas, University of Florida, Gainesville, FL Mignon L Loh, University of California at San Francisco, San Francisco, CA Michael J Borowitz, Johns Hopkins Medical Institutions, Baltimore, MD Eric C Larsen, Maine Children s Cancer Program, Scarborough, ME Leonard A Mattano Jr, Michigan State University College of Human Medicine, Kalamazoo, MI Kelly W Maloney and Stephen P Hunger, Children s Hospital Colorado and University of Colorado School of Medicine, Aurora, CO Cheryl L Willman, University of New Mexico, Albuquerque, NM Brent L Wood, University of Washington, Seattle, WA Naomi J Winick, University of Texas Southwestern Medical Center, Dallas, TX and William L Carroll and Elizabeth A Raetz, The New York University Cancer Institute, New York University Langone Medical Center, New York, NY
    J Clin Oncol 31:3397-402. 2013
    ..We investigated the impact of iAMP21 in a large cohort treated in contemporary Children's Oncology Group (COG) ALL trials...
  16. ncbi request reprint Eliminating a gold standard in childhood acute lymphoblastic leukemia?
    Elizabeth A Raetz
    Department of Pediatrics, Division of Pediatric Hematology Oncology, NYU Cancer Institute, NYU School of Medicine, New York, New York 10016, USA
    Pediatr Blood Cancer 47:242-4. 2006
  17. ncbi request reprint Identification of genes that are regulated transcriptionally by Myc in childhood tumors
    Elizabeth A Raetz
    Mount Sinai School of Medicine, New York, New York, USA
    Cancer 98:841-53. 2003
    ..Because the transforming properties of Myc are related to its ability to modulate gene expression, the authors used cDNA microarrays to identify potential Myc target genes...
  18. pmc Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia
    Julia A Meyer
    New York University Cancer Institute, New York University Langone Medical Center, New York, New York, USA
    Nat Genet 45:290-4. 2013
    ..Clinically, all individuals who harbored NT5C2 mutations relapsed early, within 36 months of initial diagnosis (P = 0.03). These results suggest that mutations in NT5C2 are associated with the outgrowth of drug-resistant clones in ALL...
  19. doi request reprint Well-differentiated pancreatic neuroendocrine carcinoma in tuberous sclerosis--case report and review of the literature
    Nicoleta C Arva
    Department of Pathology, New York University Langone Medical Center, New York, NY, USA
    Am J Surg Pathol 36:149-53. 2012
    ..We present a case of well-differentiated neuroendocrine carcinoma of the pancreas in a child with TSC and discuss the genetic aspects of this disease...
  20. ncbi request reprint "When can I go home?"-seeking ways to lower the burden on patients and families
    William L Carroll
    Division of Pediatric Hematology Oncology, Department of Pediatrics, NYU Cancer Institute, NYU School of Medicine, New York 10016, USA
    Pediatr Blood Cancer 51:318-9. 2008
  21. ncbi request reprint Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
    Elizabeth A Raetz
    Division of Pediatric Hematology Oncology, Mount Sinai School of Medicine, New York, New York, USA
    Pediatr Blood Cancer 47:130-40. 2006
    ..However, despite these similarities, differences in the clinical behavior of T-ALL and T-LL are observed...
  22. ncbi request reprint Identification of gene expression profiles that segregate patients with childhood leukemia
    Philip J Moos
    Center for Children at the Huntsman Cancer Institute and Oncological Sciences, University of Utah School of Medicine, Salt Lake City, Utah 84112, USA
    Clin Cancer Res 8:3118-30. 2002
    ....
  23. ncbi request reprint Impact of microarray technology in clinical oncology
    Elizabeth A Raetz
    Division of Hematology Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, Primary Children s Medical Center, Salt Lake City, Utah, USA
    Cancer Invest 22:312-20. 2004
    ..The dynamic nature of this field ensures that new developments are missing from this review...
  24. pmc The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas
    Elizabeth A Raetz
    Center for Children at the Huntsman Cancer Institute, Salt Lake City, Utah, USA
    Am J Pathol 161:875-83. 2002
    ..C-Myc may be a downstream target of ALK signaling and its expression a defining characteristic of ALK-positive ALCLs...